Tenaya Therapeutics Raises $92 Million for Heart Disease Research

Want to share this story?

Tenaya Therapeutics, which is in the business of discovering, developing and delivering curative therapies which target the underlying causes of heart disease, announced it just completed its latest round of funding.

The San Francisco based startup raised $92 million in Series B financing, led by Casdin Capital with the backing of GV, The Column Group, and several undisclosed new investors. It has so far raised $142 million since it was launched in October 2016 by scientists at Gladstone Institutes and University of Texas Southwestern Medical Center.

According to the  startup, the financing will be used to advance and to expand Tenaya’s pipeline and to strengthen the science, capabilities, and intellectual property that provide the foundation for Tenaya’s multi-modality product platforms – Cellular Regeneration, Gene Therapy, and Precision Medicine.

“We are now well-resourced to build on our capabilities in research and manufacturing, and to accelerate the development of our lead gene therapy and small molecule projects for both orphan and prevalent heart diseases towards the clinic,” said Faraz Ali, CEO of Tenaya, in a statement.  “We are pleased to have a group of experienced private and public investors led by Casdin Capital and The Column Group who support the potential for Tenaya’s science to transform the treatment of heart failure, the leading cause of death in the world.”

As part of the funding deal, there will be two new members of the Tenaya board of directors:  Eli Casdin, Chief Investment Officer, Casdin Capital, and Anthony Philippakis, M.D., Ph.D., Venture Partner, GV, who will join as Board Observer.